Sabra K. Salim
Hamilton, ON, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
uPAR is highly expressed in recurrent glioblastoma and represents a candidate CAR T cell target.
Journal: Science translational medicine
Published: May 13, 2026
Generation of Allogeneic CAR-T Circumvents Functional Deficits in Patient-Derived Autologous Product for Glioblastoma.
Journal: International journal of cancer
Published: August 05, 2025
In vitro evaluation of CAR-T cells in patient-derived glioblastoma models.
Journal: STAR protocols
Published: November 11, 2021
CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment.
Journal: Journal for immunotherapy of cancer
Published: October 25, 2021
Preclinical Testing of CAR T Cells in a Patient-Derived Xenograft Model of Glioblastoma.
Journal: STAR protocols
Published: December 30, 2020
The Strange Case of Jekyll and Hyde: Parallels Between Neural Stem Cells and Glioblastoma-Initiating Cells.
Journal: Frontiers in oncology
Published: September 07, 2020
Salvage therapy for progressive, treatment-refractory or recurrent pediatric medulloblastoma: a systematic review protocol.
Journal: Systematic reviews
Published: September 30, 2019
The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma.
Journal: Cell stem cell
Published: March 28, 2019
Differentiation of Brain Tumor Initiating Cells.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: October 17, 2018
Last Updated: 09/26/2026